John Ebos
LightNews LightNews
banner
ebos.bsky.social
John Ebos
@ebos.bsky.social
1.4K followers 1.7K following 76 posts
Associate Prof. in Cancer Genetics at Roswell Park Comprehensive Cancer Center studying drug resistance, metastasis, the tumor microenvironment, immunecheckpoints, and angiogenesis.

https://www.roswellpark.org/research/labs/ebos-lab
Posts Replies Media Videos
Pinned
ebos.bsky.social
John Ebos @ebos.bsky.social · Dec 11
📣New paper from our lab published in @emboreports.bsky.social 📣

Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors

@roswellpark.bsky.social @acscan.bsky.social #Cansky #oncosky #medsky #cancerresearch #drugresistance
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors | EMBO reports
imageimageAcquired resistance to PD-L1 inhibition can rewire the interferon-regulated secretory machinery in tumor cells, altering the immune microenvironment. These secretory programs may be exploite...
www.embopress.org
Reposted by John Ebos
sinclaircri.bsky.social
Coming soon! Dr. Ebos @ebos.bsky.social will be presenting in our @sinclaircri.bsky.social seminar series on Feb 26 at 4 PM. Questions? Send us an email: [email protected] #ResearchTalk #SeminarAlert #CancerResearch #CancerDrugResistance @queensuhealth.bsky.social @queensuresearch.bsky.social
February 10, 2026 at 11:36 AM
ebos.bsky.social
www.nature.com/articles/s41...
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial - Nature Medicine
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
www.nature.com
February 3, 2026 at 12:16 AM
Reposted by John Ebos
carolynbertozzi.bskyverified.social
Follow up to Doug Hanahan’s visionary article about the stages of cancer development from back in the 1990s

www.cell.com/cell/fulltex...
Hallmarks of cancer—Then and now, and beyond
Hanahan revisits the evolving framework of cancer hallmarks, synthesizing 25 years of conceptual refinement into a multidimensional view of tumor biology. This review highlights how aberrant capabilit...
www.cell.com
January 30, 2026 at 7:30 PM
ebos.bsky.social
Thank you to the American Cancer Society for highlighting our lab, this means a great deal.

Please join the Making Strides Against Breast Cancer Fundraiser October 17, 2026

www.facebook.com/groups/makin...
January 22, 2026 at 7:23 PM
ebos.bsky.social
www.nature.com/articles/s41...
Artificial intelligence agents in cancer research and oncology
Nature Reviews Cancer - Artificial intelligence agents are autonomous systems that use large language models to reason and as such can perform complex, multistep tasks with minimal human oversight....
www.nature.com
January 20, 2026 at 9:07 PM
Reposted by John Ebos
nejm.org
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg
The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 26, 2025 at 2:23 PM
ebos.bsky.social
www.cell.com/cancer-cell/...
Targeting STING to generate therapeutic anti-tumor immunity
Fahey et al. review the effects of cGAS-STING signaling in tumor cells and different cells of the tumor immune microenvironment, and discuss how these insights can inform the design of next-generation...
www.cell.com
December 24, 2025 at 9:10 PM
Reposted by John Ebos
hannahrabrams.bsky.social
🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding.

Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!
Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor. Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens. Proposed Action We propose the following approaches to make early ToDA of ICI feasible in daily routine practice: • ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment; • AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center); • ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended; • ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs; • ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.
December 21, 2025 at 5:39 PM
Reposted by John Ebos
natrevcancer.nature.com
#Review 🕯️🕯️🕯️
The ability of #macrophages to eliminate cancer cells is controlled by phagocytic checkpoints. Veillette&Co discuss targeting these checkpoints for cancer therapy and outline strategies to address therapeutic efficacy concerns.
📖⬇️
Targeting phagocytosis checkpoints for cancer immunotherapy - Nature Reviews Cancer
Macrophages can eliminate cancer cells through phagocytosis, which is tightly regulated through inhibition and activation of various phagocytic receptors. In this Review, Veillette and colleagues outline how targeting these phagocytic checkpoints could be harnessed therapeutically, address therapeutic efficacy concerns, and propose strategies to enhance therapeutic outcomes in future clinical applications.
bit.ly
December 15, 2025 at 4:30 PM
ebos.bsky.social
www.nature.com/articles/s42...
LLM use in scholarly writing poses a provenance problem - Nature Machine Intelligence
Nature Machine Intelligence - LLM use in scholarly writing poses a provenance problem
www.nature.com
December 14, 2025 at 3:47 PM
ebos.bsky.social
www.onclive.com/view/china-s...
China’s Center for Drug Evaluation Grants Breakthrough Therapy Designation to Ivonescimab in TNBC | OncLive
Ivonescimab plus chemotherapy has received breakthrough therapy designation as first-line therapy in patients with triple-negative breast cancer.
www.onclive.com
November 19, 2025 at 3:53 AM
ebos.bsky.social
Review: Linking tumour angiogenesis and tumour immunity
Linking tumour angiogenesis and tumour immunity - Nature Reviews Immunology
Tumour-associated blood vessels are abnormal in structure and function, and this can limit immune cell infiltration into tumours and contribute to the immunosuppressive tumour microenvironment. This R...
www.nature.com
November 16, 2025 at 5:22 PM
Reposted by John Ebos
marcus-ruscetti.bsky.social
How can senescent cells, which are damaged and growth arrested, both block tumor initiation as well as fuel its growth? A recent study published in Cancer Discovery @aacrjournals.bsky.social from Lin Zhou in the lab uncovered some new insights into this puzzle.
aacrjournals.org/cancerdiscov...
P21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy
Abstract. Cellular senescence is a well-established tumor-suppressive cell cycle arrest program. However, chronic inflammation through the senescence-associated secretory phenotype (SASP) can alternat...
aacrjournals.org
October 29, 2025 at 2:40 PM
ebos.bsky.social
aacrjournals.org/cancerdiscov...
Rethinking Cancer Drug Development through Tumor-Agnostic Precision Medicine
Summary:. Tumor-agnostic therapies represent a revolutionary shift from century-old anatomic classifications to molecular-driven cancer treatment, in which therapeutic decisions are based on what driv...
aacrjournals.org
October 20, 2025 at 5:21 PM
Reposted by John Ebos
natrevdrugdiscov.nature.com
For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms
rdcu.be/eLS8A
www.nature.com/articles/s41...
Metabolites as agents and targets for cancer immunotherapy
Nature Reviews Drug Discovery - Tumour cells undergo profound changes in their metabolism, but targeting these metabolic pathways requires understanding of the impact on immune cells as well as...
rdcu.be
October 20, 2025 at 2:47 PM
Reposted by John Ebos
nycures.bsky.social
🚀 NY-CURES Launch — Championing State-Wide Investment in Science! 🚀

Our new coalition advocates for sustained public support of New York’s vibrant biomedical research ecosystem — creating cures, economic gains & strengthening communities.

Sign up. Stay informed. Join the movement: www.nycures.org/
September 4, 2025 at 4:32 PM
ebos.bsky.social
www.nature.com/articles/s41...
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer - Nature Reviews Drug Discovery
CD8 T cells and natural killer (NK) cells play a key role in cancer immunosurveillance. However, their anticancer activity is rapidly diminished in the tumour microenvironment, associated with a decli...
www.nature.com
September 11, 2025 at 6:41 PM
ebos.bsky.social
Review: Targeting the peripheral neural-tumour microenvironment for cancer therapy
Targeting the peripheral neural-tumour microenvironment for cancer therapy - Nature Reviews Drug Discovery
Targeting the interactions between neurons, cancer cells and other elements in the tumour microenvironment represents a potential paradigm shift in cancer treatment. This Review article provides an ov...
www.nature.com
September 7, 2025 at 3:48 PM
Reposted by John Ebos
vjsanchez.bsky.social
Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling 🧪 #PancreaticCancer gut.bmj.com/content/74/9...
Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling
Background Cancer-associated fibroblasts (CAFs) are highly heterogeneous in the progression of pancreatic ductal adenocarcinoma (PDAC) and vasculogenic mimicry (VM) refers to a phenomenon in which can...
gut.bmj.com
September 4, 2025 at 2:19 PM
ebos.bsky.social
Happy to share our @bio-protocol.bsky.social describing an ex vivo method to measure CD8+ T-cell function. This was used in our recent papers in @emboreports.org (2025) and Molecular Cancer Therapeutics (2024).

Thanks to Melissa Dolan for leading this effort - Congratulations to the whole team!
Isolation and Ex Vivo Testing of CD8+ T-Cell Division and Activation Using Mouse Splenocytes
This protocol describes an ex vivo co-culture method to assess CD8+ T-cell activation, proliferation, and cytotoxic potential using bulk splenocytes isolated from immunocompetent mice. Mouse splenocyt...
bio-protocol.org
August 22, 2025 at 7:43 PM
Reposted by John Ebos
labwaggoner.bsky.social
TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation
@cp-cellrepmed.bsky.social
@mklevings.bsky.social
cell.com/cell-reports...
August 19, 2025 at 8:30 PM
ebos.bsky.social
aacrjournals.org/cancerimmuno...
Sustained Macrophage Reprogramming Is Required for CD8+ T cell–Dependent Long-Term Tumor Eradication
Tumor-associated macrophages typically support tumor growth but can be reprogrammed to an antitumor phenotype. The authors show that repeated administration of tumor-associated macrophage–targeting tr...
aacrjournals.org
August 19, 2025 at 7:47 PM
Reposted by John Ebos
sandramcallister.bsky.social
It’s out!!!!! We hope our review on aging, immunity, and cancer is helpful.

Such a rewarding group effort led by Melissa Dolan, with Kendra Libby, Alison Ringle, and @vangalenlab.bsky.social

So grateful to @gabriellebrewer.bsky.social @natrevcancer.nature.com for her efforts and support
August 14, 2025 at 1:17 PM
Reposted by John Ebos
science.org
The appearance of large language models caused a drastic shift in the vocabulary of academic writing, according to an analysis in #ScienceAdvances of more than 15 million biomedical abstracts published from 2010 to 2024.

Learn more:
Delving into LLM-assisted writing in biomedical publications through excess vocabulary
Large language models (LLMs) like ChatGPT can generate and revise text with human-level performance. These models come with clear limitations, can produce inaccurate information, and reinforce existing biases.
scim.ag
August 10, 2025 at 2:07 PM
ebos.bsky.social
Editorial: Immune modulation and angiogenesis in regenerative and developmental processes.
Frontiers | Editorial: Immune modulation and angiogenesis in regenerative and developmental processes
The immune system plays a pivotal role not only in host defense and inflammation but also in tissue development, regeneration, and repair. Similarly, angioge...
www.frontiersin.org
August 10, 2025 at 1:59 AM